Lymphocyte Predominant Hodgkin Lymphoma

Brandon McMahon*, Jonathan W. Friedberg, Ralph M. Meyer

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Original languageEnglish (US)
Title of host publicationEvidence-Based Hematology
PublisherJohn Wiley and Sons
Number of pages6
ISBN (Print)9781405157476
StatePublished - Feb 4 2009


  • De novo LPHL and classical Hodgkin lymphoma treatment
  • Detection and treatment of LPHL progression or relapse
  • LPHL - distinct clinical/pathologic entity from classical HL
  • Literature-search strategy and inclusions
  • Lymphocyte predominant Hodgkin lymphoma (LPHL)
  • Rituximab - active agent in LPHL
  • Rituximab - included as "standard" therapeutic modality for LPHL

ASJC Scopus subject areas

  • Medicine(all)

Cite this